Authors: By Dr. Liji Thomas, MD Reviewed by Emily Henderson, B.Sc. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can cause inflammatory lung disease, including clot formation and hyper-permeability of the lung vessels, resulting in edema and bleeding into the lung. Inflammation also affects other organs, mediated by the cytokine storm. This inflammation is characterized by endothelial cell […]
Salk researchers and collaborators show how the protein damages cells, confirming COVID-19 as a primarily vascular disease April 30, 2021 LA JOLLA—Scientists have known for a while that SARS-CoV-2’s distinctive “spike” proteins help the virus infect its host by latching on to healthy cells. Now, a major new study shows that the virus spike proteins […]
Authors: Xuhua Xia1,2Kenneth Lundstrom, Academic Editor and Alaa. A. A. Aljabali, Academic Editor Abstract The spike protein in SARS-CoV-2 (SARS-2-S) interacts with the human ACE2 receptor to gain entry into a cell to initiate infection. Both Pfizer/BioNTech’s BNT162b2 and Moderna’s mRNA-1273 vaccine candidates are based on stabilized mRNA encoding prefusion SARS-2-S that can be produced after the mRNA […]
Authors: Analysis by Dr. Joseph Mercola STORY AT-A-GLANCE mRNA-based COVID shots have used codon optimization to improve protein production. A codon consists of three nucleotides, and nucleotides are the building blocks of DNA. Use of codon optimization virtually guarantees unexpected results Replacing rare codons must be done judiciously, as rarer codons can have slower translation rates […]
Authors: Jackson S. Turner, Wooseob Kim, Elizaveta Kalaidina, Charles W. Goss, Adriana M. Rauseo, Aaron J. Schmitz, Lena Hansen, Alem Haile, Michael K. Klebert, Iskra Pusic, Jane A. O’Halloran, Rachel M. Presti & Ali H. Ellebedy Abstract Long-lived bone marrow plasma cells (BMPCs) are a persistent and essential source of protective antibodies1,2,3,4,5,6,7. Individuals who have recovered from COVID-19 have a substantially lower risk of reinfection with SARS-CoV-28,9,10. Nonetheless, […]
